LABGENOMICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,755 KRW | +0.73% |
|
+1.29% | -28.53% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 280,899 | 214,147 | 286,195 | 204,531 | - |
| Enterprise Value (EV) 2 | 280.9 | 214.1 | 286.2 | 111.5 | 105.5 |
| P/E ratio | - | - | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 1.39 x | 1.49 x | 5.58 x | 1.84 x | 1.4 x |
| EV / Revenue | 1.39 x | 1.49 x | 5.58 x | 1 x | 0.72 x |
| EV / EBITDA | - | - | - | 8.92 x | 4.19 x |
| EV / FCF | 5.47 x | - | - | -29.4 x | 17.3 x |
| FCF Yield | 18.3% | - | - | -3.41% | 5.78% |
| Price to Book | 1.8 x | - | - | 0.97 x | 0.91 x |
| Nbr of stocks (in thousands) | 67,416 | 67,983 | 74,240 | 74,240 | - |
| Reference price 3 | 4,167 | 3,150 | 3,855 | 2,755 | 2,755 |
| Announcement Date | 3/23/22 | 3/13/23 | 3/20/24 | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | 202.3 | 143.5 | 51.3 | 111.3 | 146.6 |
| EBITDA 1 | - | - | - | 12.5 | 25.2 |
| EBIT 1 | 105.5 | 70.14 | -2.365 | 4.7 | 17.1 |
| Operating Margin | 52.13% | 48.86% | -4.61% | 4.22% | 11.66% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | - | - | - | - | - |
| Free Cash Flow 2 | 51,383 | - | - | -3,800 | 6,100 |
| FCF margin | 25,400.75% | - | - | -3,414.2% | 4,160.98% |
| FCF Conversion (EBITDA) | - | - | - | - | 24,206.35% |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/23/22 | 3/13/23 | 3/20/24 | - | - |
1KRW in Billions2KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 53.41 | 60.97 | 9.705 | 22.2 | 24.4 | 27.4 | 37.3 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | 29.68 | 35.19 | -6.019 | -1.4 | -0.1 | 2.5 | 3.7 |
| Operating Margin | 55.58% | 57.72% | -62.02% | -6.31% | -0.41% | 9.12% | 9.92% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 3/23/22 | 3/20/24 | - | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 93 | 99 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 2 | 51,383 | - | - | -3,800 | 6,100 |
| ROE (net income / shareholders' equity) | - | - | - | 1.8% | 6.4% |
| ROA (Net income/ Total Assets) | - | - | - | 1.5% | 5.4% |
| Assets | - | - | - | - | - |
| Book Value Per Share 3 | 2,312 | - | - | 2,827 | 3,013 |
| Cash Flow per Share | 966.0 | - | - | - | - |
| Capex 1 | 13.7 | - | - | 10 | 10 |
| Capex / Sales | 6.78% | - | - | 8.98% | 6.82% |
| Announcement Date | 3/23/22 | 3/13/23 | 3/20/24 | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.53% | 148M | |
| -17.86% | 8.35B | |
| +42.03% | 3.58B | |
| -8.06% | 2.47B | |
| -38.71% | 2.46B | |
| -7.96% | 2.36B | |
| -15.36% | 1.78B | |
| -19.73% | 1.53B | |
| -40.78% | 1.21B | |
| +8.32% | 1.12B |
- Stock Market
- Equities
- A084650 Stock
- Financials LabGenomics Co., Ltd.
